Grant: Travel Awards - Institute Community Support
University of Toronto
$5,000.00
Fc gamma receptors signalling after engaging IVIG in monocyte/macrophage
FY 2015-16
Summary
Background: Intravenous immunoglobulin (IVIG) is a blood product pooled and purified from the plasma of thousands of blood donors. Currently, IVIG therapy has been approved for a multitude of diseases ranging from immunodeficiency to neurological disorders in Canada. Despite the long history and extensive use of IVIG in clinics, the precise molecular immunomodulatory mechanisms are still not well understood. Multiple mechanisms have been suggested, however, there is a lack of consensus. This is likely due to 1) IVIG functions through different mechanisms in different diseases, and 2) that the use of various animal models might not fully recapitulate the mechanisms in humans due to differences in physiology.
Significance of the proposed study: The efficacy of IVIG has been well documented in a number of mouse models recapitulating immune disorders, especially those involving pathological antibodies and subsequent destruction of host tissues/cells by effector immune cells. Preliminary data from a cell-based assay suggest that the simple mechanism of IVIG directly binding to activating Fc gamma R and/or blocking effector immune functions does not explain the robust efficacy of IVIG observed at the whole organism level. Our data suggest that IVIG might modulate immune responses in an indirect way through signalling and downstream regulation of the immune system as a whole.
Research Approach: With the use of effector immune cells derived from the bone marrow and whole blood of mice, we aim to identify the receptor(s) necessitating IVIG binding, characterize the downstream signalling of IVIG and the potential activation of anti-inflammatory factors.
Department
Program
Travel Awards - Institute Community Support
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
347114
Name
Tong Tik Nga
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Institute of Genetics
Projecttitle
Fc gamma receptors signalling after engaging IVIG in monocyte/macrophage
Programtype2
Undefined
Orgnameinp2
University of Toronto
Cihramount2
$5,000
Cihrequipment2
$0
Programname2
Travel Awards - Institute Community Support
Keyworddelim
Ics Travel Awards
Abstract
Background: Intravenous immunoglobulin (IVIG) is a blood product pooled and purified from the plasma of thousands of blood donors. Currently, IVIG therapy has been approved for a multitude of diseases ranging from immunodeficiency to neurological disorders in Canada. Despite the long history and extensive use of IVIG in clinics, the precise molecular immunomodulatory mechanisms are still not well understood. Multiple mechanisms have been suggested, however, there is a lack of consensus. This is likely due to 1) IVIG functions through different mechanisms in different diseases, and 2) that the use of various animal models might not fully recapitulate the mechanisms in humans due to differences in physiology.
Significance of the proposed study: The efficacy of IVIG has been well documented in a number of mouse models recapitulating immune disorders, especially those involving pathological antibodies and subsequent destruction of host tissues/cells by effector immune cells. Preliminary data from a cell-based assay suggest that the simple mechanism of IVIG directly binding to activating Fc gamma R and/or blocking effector immune functions does not explain the robust efficacy of IVIG observed at the whole organism level. Our data suggest that IVIG might modulate immune responses in an indirect way through signalling and downstream regulation of the immune system as a whole.
Research Approach: With the use of effector immune cells derived from the bone marrow and whole blood of mice, we aim to identify the receptor(s) necessitating IVIG binding, characterize the downstream signalling of IVIG and the potential activation of anti-inflammatory factors.
Competitiondate
201601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tong, Tik Nga
Approvedterm
1 an 0 mois
Cihrcontribution2
Institute of Genetics~ $5,000~ $0~